ArticleTranslational oncology2026
EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionImmunotherapy recently approved with first-line (1L) chemotherapy for advanced biliary tract cancer (aBTC). Translational research is warranted to identify biomarkers for efficacy.
methodsThis prospective multicenter non-randomised phase-II study recruited 50 treatment-naïve proven aBTC patients for cisplatin and gemcitabine with pembrolizumab until disease progression or unacceptable toxicity. Primary endpoint was progression-free survival at 6 months (6mPFS, RECIST v.1.1). Secondary endpoints were overall survival (OS), radiological responses and safety. Exploratory translational research was to identify predictive biomarkers. Tumour tissue and blood were collected for MMR, PD-1/PD-L1 in T-cells, monocytes and myeloid derived suppressor cells (MDSCs).
resultsFifty patients were 38% male, aged 63 (35-84) years. 6mPFS was 61.2% (80% CI 51.7-69.5) with mPFS 8.3 months (95% CI 5.6-10.6); ORR 40.8% (95% CI 27.0-55.8). Med. OS was 13.4 months (95% CI 8.3-20.5) with 24-months-OS 28.4% (95% CI 16.6-41.4). Higher PD-L1 expression correlated with improved PFS (HR=0.59; 95% CI: 0.26-1.37) and OS (HR=0.68; 95% CI: 0.28-1.64). Responders showed higher CD8/Treg ratio than non-responders (26.2% vs 21.2%) and lower CD4/PD1+ and CD8/PD1+ T-cells (33.5% vs 41.5% and 26.4% vs 44.7%) respectively. During treatment, profiling decreased in CD4/PD1+ and CD8/PD1+ Tcells (36.0% vs 22.2% and 41.6% vs 21.0%) respectively. MDSCs increased in non-responders. Responders, CPS-positive and low-stage patients showed normal Neutrophil-Lymphocyte-Ratios.
conclusionPembrolizumab plus CisGem showed consistent efficacy to prior phase-III trials. Biomarkers suggest baseline immune landscape influences responses, T-cell exhaustion and immunosuppressive myeloid expansion. Immune phenotyping supports patient selection and further biomarker-driven trials in BTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.